Managing Hyperkalemia With Novel Potassium Binders to Achieve Optimal Outcome
This webcast is based on live proceedings from a symposium conducted at the 2019 Cardiometabolic Risk Summit.
Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.
James J. Matera, DO, FACOI
Sr. VP of Medical Affairs and CMO
CentraState Medical Center
Freehold, New Jersey
This activity is designed for primary care physicians, family medicine specialists, internists, pediatricians, nurse practitioners, nurses, physician assistants, pharmacists, registered dietitians, certified diabetes educators, and other related healthcare professionals involved in the treatment of patients at risk for cardiometabolic syndrome.
After completing this activity, participants should be able to:
- Outline the association between cardiometabolic diseases and hyperkalemia
- Discuss benefits and risks of various treatment approaches for chronic hyperkalemia, including the effects of RAAS discontinuation
- Outline efficacy and safety data of novel potassium binder medications
- Incorporate the use of novel potassium binder medications into clinical practice for appropriate patients with hyperkalemia who would benefit from RAAS therapy continuation
